EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors

Susan C Scott, Anna Farago, W Victoria Lai, Marianna Zahurak, Michelle A Rudek, Judy Murray, Michael A Carducci, Tamar Uziel, Naoko Takebe, Steven D Gore, Charles M Rudin, Christine L Hann

Cancer Chemotherapy and Pharmacology · 2025-12 · 95 (1)

DOI: 10.1007/s00280-025-04760-1 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 25.02.2025. Verfasst von Susan C Scott und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To determine the, safety, tolerability and recommended phase 2 dosing of the combination of navitoclax, a dual Bcl-2/xL inhibitor, and vistusertib, a TORC1/2 inhibitor. METHODS: Patients with advanced solid tumors received navitoclax plus vistusertib following a 3 + 3 dose escalation design. To mitigate thrombocytopenia, a known toxicity of navitoclax, all patients received lead-in dosing of navitoclax alone at 150 mg orally daily for a minimum of 7 days. In addition to safety and tolerability, pharmacokinetics of navitoclax and vistusertib were evaluated. RESULTS: 14 patients received combination treatment which was well-tolerated at dose level 1 (navitoclax 150 mg orally daily plus vistusertib 35 mg orally twice daily). The main dose-limiting toxicity, grade 3 serum aminotransferase elevation, occurred in two of five patients at dose level 2 (navitoclax 250 mg orally daily plus vistusertib 35 mg orally twice daily). Navitoclax and vistusertib exposures appeared consistent with levels reported in prior studies of each agent. No responses were observed among the 8 response evaluable patients. CONCLUSIONS: A tolerable dose of navitoclax at 150 mg orally daily plus vistusertib at 35 mg orally twice daily was identified in patients with advanced solid tumors and established as the recommended phase 2 dose (RP2D). Further efficacy assessment of this combination, in a planned phase 2 expansion in patients with relapsed small cell lung cancer, was terminated due to discontinuation of vistusertib. TRIAL REGISTRATION: NCT03366103 (First posted December 8, 2017).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAniline CompoundsAgedMiddle AgedSulfonamidesMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2AdultIndolesDose-Response Relationship, DrugBenzamidesMorpholinesPyrimidines

Substanzen

Aniline CompoundsnavitoclaxSulfonamidesMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2vistusertibIndolesBenzamidesMorpholinesPyrimidines

Autor:innen und Institutionen

  • Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
  • Krantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Oncology Biostatistics, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
  • Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
  • Oncology Discovery, AbbVie Inc, North Chicago, IL, USA.

Förderung

  • NCI NIH HHS
  • NCI

Zitieren

APA

Scott, S. C., Farago, A., Lai, W. V., Zahurak, M., Rudek, M. A., Murray, J., Carducci, M. A., Uziel, T., Takebe, N., Gore, S. D., Rudin, C. M., & Hann, C. L. (2025). A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 95(1). https://doi.org/10.1007/s00280-025-04760-1

Vancouver

Scott SC, Farago A, Lai WV, Zahurak M, Rudek MA, Murray J, et al. A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 2025;95(1). doi:10.1007/s00280-025-04760-1

BibTeX
@article{Scott2025,
  author = {Scott, Susan C and Farago, Anna and Lai, W Victoria and Zahurak, Marianna and Rudek, Michelle A and Murray, Judy and Carducci, Michael A and Uziel, Tamar and Takebe, Naoko and Gore, Steven D and Rudin, Charles M and Hann, Christine L},
  title = {A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  volume = {95},
  number = {1},
  doi = {10.1007/s00280-025-04760-1}
}
Kostenlos starten →